baber/WOPTO huggingface dataset:
Patent CY-1120261-T1 (CY)
Title: Θεραπευτικα εμβολια
Inventor: MATSOUKAS JOHN
IPC: C07K14/47
Filed: 2018-05-18
Abstract: Μια πρώτη πτυχή της εφεύρεσης σχετίζεται με ένα προϊόν σύζευξης που περιλαμβάνει: (i) μαννάνη• και (ii) τουλάχιστον έναν επίτοπο που περιλαμβάνει ένα τμήμα πεπτιδίου μίας πρωτεΐνης που επιλέγεται από τη βασική πρωτεΐνη της μυελίνης (ΜΒΡ), την γλυκοπρωτεΐνη μυελίνης ολιγοδενδροκυττάρων (MOG) και την πρωτεΐνη πρωτεολιπιδίου (PLP), με το εν λόγω τμήμα πεπτιδίου να είναι σε γραμμική κυκλική μορφή• όπου ο εν λόγω επίτοπος είναι συζευγμένος με τη μαννάνη μέσω μιας γέφυρας [(LyS-GIy)n], όπου το n είναι ένας ακέραιος από το 1 έως το 10. Περαιτέρω πλευρές της εφεύρεσης σχετίζονται με φαρμακευτικές συνθέσεις που περιλαμβάνουν τα εν λόγω προϊόντα σύζευξης, και τη χρήση τους στην παρασκευή ενός φαρμάκου για τη θεραπεία μιας διαταραχής του ανοσοποιητικού.
Patent HR-P20090237-T1 (HR)
Inventor: MUTTI STUPHANE
IPC: C07D281/10
Filed: 2009-04-22
Abstract: Postupak dobivanja 2-imino-9-trifluormetil-4,5-dihidro-2H,7H-tiazolo[3,4,5-de][4,1]benzotiazepin-6,6-dioksid-metansulfonata, naznačen time štoa)	4-trifluormetilanilin se zaštićuje u prisutnosti di-tert-butil-dikarbonata u monoklorbenzenu, na refluksu, zatimb)	tert-butil-4-trifluormetilfenilkarbamat, izdvojen u prethodnom koraku, se prevodi u 2-hidroksimetil-4-trifluormetilfenilkarbamat, bez izdvajanja 2-formil-4-trifluormetilfenilkarbamata kao međuprodukta, zatimc)	2-hidroksimetil-4-trifluormetilfenilkarbamat, izdvojen u prethodnom koraku, se izravno prevodi u 7-trifluormetil-1,5-dihidro-3H-[4,1]benzotiazepin-2-on, u prisutnosti tioglikolne kiseline i katalitičke količine p-toluensulfonske kiseline, zatimd)	7-trifluormetil-1,5-dihidro-3H-[4,1]benzotiazepin-2-on, izdvojen u prethodnom koraku, se reducira kako bi se dobilo 7-trifluormetil-1,2,3,5-tetrahidro-[4,1]benzotiazepin, zatime)	7-trifluormetil-1,2,3,5-tetrahidro-[4,1]benzotiazepin, izdvojen u prethodnom koraku, se prevodi u 2-imino-9-trifluormetil-4,5-dihidro-2H,7H-tiazolo[3,4,5-de][4,1]benzotiazepin-hidrobromid, u prisutnosti broma i kalijevog tiocijanata u octenoj kiselini, i zatimf)	2-imino-9-trifluormetil-4,5-dihidro-2H,7H-tiazolo[3,4,5-de][4,1]benzotiazepin-hidrobromid, se oksidira u 2-imino-9-trifluormetil-4,5-dihidro-2H,7H-tiazolo[3,4,5-de][4,1]benzotiazepin-6,6-dioksid, a zatim, u prisutnosti metansulfonske kiseline, prevodi u 2-imino-9-trifluormetil-4,5-dihidro-2H,7H-tiazolo[3,4,5-de][4,1]benzotiazepin-6,6-dioksid-metansulfonat. Patent sadrži još 14 patentnih zahtjeva.
Patent HR-P20110406-T1 (HR)
Title: (r)-4-(heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them
Inventor: MORICONI ALESSIO
IPC: A61P37/00
Filed: 2011-05-31
Abstract: The present invention relates to a novel class of (R)-4-(heteroaryl)phenylpropionic derivatives of formula (I), useful in the inhibition of the chemotactic activation induced by the fraction C5a of complement. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement. In particular, the compounds of the invention are useful in the treatment of autoimmune hemolytic anemia (AIHA), psoriasis, bullous pemphigoid, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion.
Patent HR-P20120282-T1 (HR)
Title: Lifting system
Inventor: WEDEL HENNING VON
IPC: B63B21/50
Filed: 2012-03-29
Abstract: A lifting system for navigable watercraft or marine vessels for temporary stationary positioning of the vessel on a seabed includes supporting legs that may be lowered and raised, and a locking and braking device to provide a force locking engagement with the respective supporting leg. The lifting system also includes a hydro-mechanical device, combined with hydraulic devices, to allow a stationary position of a raised vessel and a lowering of the vessel during transition to a travelling position to be achieved.
Patent SI-1605957-T1 (SI)
Title: The use of lupin conglutin for the treatment of type ii diabetes
Inventor: MORAZZONI PAOLO
IPC: A23L33/00
Filed: 2004-02-06
Abstract: A method for the use of lupin conglutin gamma or of proteins showing homology higher than 50% with lupin conglutin gamma, for the preparation of a medicament, food supplements or foods for the treatment of type II diabetes, pharmaceutical and nutritional compositions containing lupin conglutin gamma, and the use of lupin conglutin gamma as therapeutical agent, in particular as hypoglycemizing agent. Lupin conglutin gamma may be used in pure form or in form of extracts, mixtures or concentrates.
Patent SI-1672017-T1 (SI)
Title: Rubber compositions
Inventor: ALBERT PHILIPP
IPC: C08L9/06
Filed: 2005-12-14
Abstract: Rubber mixture (A) comprises rubber, fillers, optionally rubber auxiliary agent and at least an organosilane compound (I). Rubber mixture (A) comprises rubber, fillers, optionally rubber auxiliary agent and at least an organosilane compound (I) of formula (R 1>R 2>R 3>SiR 4>-SH). R 1>methyl or ethyl; R 2>ethoxy, ethoxy or -O-(Y 1>-O) m-X; Y 1>optionally saturated double bonded hydrocarbon group; X : 1-9 alkyl group; R 3>methyl, ethyl or R 2>; R 4>optionally saturated, aliphatic and/or aromatic double bonded 1-12C hydrocarbon group; and m : 1-40.
Patent SI-2016794-T1 (SI)
Title: Method for optimizing the load distribution between a first mobile radio network and a second mobile radio network
Inventor: KLATT AXEL
IPC: H04W28/00
Filed: 2007-05-03
Abstract: A method for optimizing the load distribution between one mobile radio network, for example using the UMTS standard, and another mobile radio network, for example using the GSM standard, by optimizing the signalling sequence when establishing a connection in such a mobile radio system. It enables efficient cooperation when establishing a connection, for example a voice connection, between a UMTS and a GSM network. In addition to the efficient use of resources in a UMTS system, the method also enables direct establishment of a connection, for example of a voice connection that was initiated in a UMTS network, in a GSM network.
Patent SI-1991201-T1 (SI)
Title: Nebulised antibiotics for inhalation therapy
Inventor: KELLER MANFRED
IPC: A61K31/00
Filed: 2007-02-08
Abstract: The present invention provides pharmaceutical aerosols which are useful for the prevention or treatment of infectious diseases of the airways, such as the lungs, the bronchi, or the sinunasal cavities. The aerosols comprise an active agent selected from the group of quinolone antibiotics. Also disclosed are liquid and solid compositions suitable for being converted into the aerosols, and kits comprising such compositions.
Patent SI-3046778-T1 (SI)
Title: Thermo transfer films for the dry lacquering of surfaces
Inventor: BIEHLER MANFRED
IPC: B44C1/00
Filed: 2014-09-18
Abstract: The present invention relates to heat transfer films, comprising: a) a carrier film (2), b) at least one, for example one, two or three, coating layer(s) (3) arranged directly on the carrier film (2), c) at least one, in particular precisely one, hot-sealable polymer adhesive layer (4), wherein the coating layer is based on a non-aqueous, radiation-curable, liquid composition which contains at least 60 wt %, in particular at least 70 wt %, based on the total weight of the composition, curable constituents selected from organic oligomers which have ethylenically unsaturated double bonds and mixtures of these oligomers with monomers which have at least one ethylenically unsaturated double bond. The invention also relates to the use of the heat transfer films for the dry coating of surfaces. The invention also relates to the production of such heat transfer films and to a method for coating or lacquering surfaces of objects using the heat transfer films according to the invention.
Patent DE-3486479-T2 (DE)
Inventor: INOUYE MASAYORI
IPC: C12N1/21
Filed: 1984-10-19
Granted: 2001-09-20
Abstract: Gene expression of the genetic material of cellular material or an organism is regulated or inhibited by incorporating in or along with the genetic material of the cellular material or organisms DNA or other genetic material which transcribes to an RNA which is complementary to and capable of binding to the mRNA of the genetic material of said organism. Gene expression or regulation of a gene is controlled by expressing a DNA fragment or replica of said gene inserted or positioned after a promoter in the opposite direction relative to the gene so as to regulate or inhibit the expression of said gene.
Patent DE-3779913-T2 (DE)
Inventor: ROSE GENE D
IPC: C11D3/39
Filed: 1987-07-10
Granted: 1992-12-10
Abstract: Bleach compositions, such as aqueous sodium hypochlorite formulations, are thickened by admixing the composition with a viscoelastic surfactant. Viscoelastic surfactants comprise surfactant ions and organic counterions that associate in the bleach composition to form the viscoelastic surfactant. Thickened bleach compositions of this invention exhibit bleach stability, phase stability, and viscosity stability for acceptably long periods of time. The thickened bleach compositions can be employed as nonmisting sprays and streams which will stick to vertical surfaces without substantial dripping and can be applied to various substrates using a dispensing device.
Patent DE-3783039-T2 (DE)
Inventor: LEIGH STEVEN
IPC: A61K9/10
Filed: 1987-06-05
Granted: 1993-06-24
Abstract: Compositions that are sprayable or that are in the form of discrete particles and that contain a lipid and a biologically active compound in the form of a micronised powder combine a high initial entrapment of the active compound in the membrane lipid with sustained release at the site of application as indicated by in-vitro and in-vivo tests. In a first form pro-liposomes are prepared by spraying under pressure through a nozzle a single composition comprising at least one volatile liquid propellant, at least one membrane lipid that is at least partly dissolved or dispersed in the propellant and at least one biologically active compound that is present in dispersion in the propellant and/or the lipid, the composition being free from other solvent for the lipid. In a second form the membrane lipid and the biologically active compound are minor components of micronised solid particles whose major component is a physiologically acceptable solid carrier.
Patent DE-3785041-T2 (DE)
Inventor: SIVAK J
IPC: C08F30/08
Filed: 1987-12-28
Granted: 1993-07-01
Abstract: A monomer exhibiting polar functionality such as through a hydroxyl group or other functional group is protected during polymerization in the presence of highly active catalysts by the use of a protective alkyl silane group which is removed after polymerization to restore the functionality of the group. The polymer thus made will have functional groups on its backbone; the functional groups may be reacted with conventional dyes and/or may perform other functions and enter reactions with other reactive compounds. New copolymers are disclosed to be made in Ziegler-Natta systems.
Patent DE-3851262-T2 (DE)
Inventor: NAKAI HISAO
IPC: A61K31/19
Filed: 1988-05-06
Granted: 1995-02-02
Abstract: A benzoylaminophenoxybutanoic acid derivative of general formula:   <CHEM> [wherein A represents oxygen, sulfur or sulfinyl, R<1> represents hydrogen or methyl, R<2> represents a group of the general formula: <CHEM>  [wherein  B represents oxygen, sulfur or NR sec  (wherein R sec  represents hydrogen or alkyl, R<3>, R<4>, R<5>, R<6>, R<7> and R<8> represent independently, hydrogen, alkyl, halogen or trifluoromethyl, m represents 0 or 1, n is from 1 to 4, and R<9> and R<1><0> represent, independently, hydrogen, alkyl, optionally substituted phenylalkyl, optionally substituted benzoyl or tetrahydronaphthyl, with the proviso that R<9> and R<1><0> do not simultaneously represent hydrogen or non-toxic salts thereof, possess inhibitory activity on 5 alpha -reductase, which is indicative of utility in treating and/or preventing alopecia, acne or prostatic hypertrophy.
Patent DE-3853994-T2 (DE)
Inventor: MACNAK PHILIP
IPC: H04B1/38
Filed: 1988-03-24
Granted: 1996-02-01
Abstract: A personal communications device is described including a receiver (16), intended to be worn on the body, which receives, detects and stores messages transmitted on a first communication channel (14). The stored message is then transmitted over a second communications channel (20) to a second receiver (22) which is intended to be worn on the wrist. The second receiver (22) receives, detects and stores the message, and presents the message to the user in the form of a visual display. A system transmitting synchronization signals and coded message signals is also described. In particular, coded synchronization signals are used to indicate the transmission of coded message signals or the absence of transmission of coded message signals following the transmission of the coded synchronization signal, thereby providing a battery saving function for a personal communications receiver.
Patent DE-3878411-T2 (DE)
Inventor: MARTIN TIMOTHY JOHN
IPC: C09J7/29
Filed: 1988-11-18
Granted: 1993-06-24
Abstract: A structure for use in covering surfaces of buildings having a sheet like substrate and contiguous thereto a membrane of a water proofing pressure sensitive adhesive, wherein a sheet like substrate is a combination of a laminated biaxially oriented polyethylene with a film of a compatable and pigmented polymer formed on the surface of the polyethylene remote from the adhesive membrane.
Patent DE-3880691-T2 (DE)
Inventor: FUJII GARY
IPC: A61P35/00
Filed: 1988-11-03
Granted: 1993-08-12
Abstract: Liposomes with hyperosmotic concentration of compounds encapsulated therein are targeted to tumors for neutron capture therapy. The compounds have an element with a large neutron capture cross section and an isotope that emits alpha particles when bombarded with neutrons. A method employing such liposomes for neutron capture therapy is also described.
Patent TR-199900206-T2 (TR)
Inventor: PODWIRNY PHILIP S
IPC: C10G11/18
Filed: 1997-07-25
Abstract: Bir hidrokarbon kraking katalizörü üzerindeki kirletici metalin pasiflestirilmesi için bir islem saglanmistir. Katalizör, bir hidrokarbon katalitik kraking ünitesi içinde dengelenmis bir dispersiyon ile temas ettirilir. Dispersiyon, bir akiskan vasitayi, dagitici bir maddeyi ve metalle kirlenmis kraking katalizörlerinin pasiflestirilmesi için bir veya daha fazla metalin veya metal bilesiginin ince ögütülmüs taneciklerini içerir. Dispersiyon tercihen çalkalama vasitali bir ögütücünün, ufalayici vasitalarla, akiskan vasitayla, dagitici maddeyle ve metalle kirlenmis kraking katalizörlerinin pasiflestirilmesi için bir metal veya metal bilesiginin tanecikleriyle yüklenir. Ufalayici vasitalar, akiskan vasita ve tanecikler daha sonra taneciklerin boyutu en azindan %10 küçültülene ve 0.5 mikrondan küçük bir hacimsel ortalamali tanecik boyutuna sahip olana degin çalkalanir.
Patent TR-199900993-T2 (TR)
Inventor: LEENSLAG JAN WILLEM
IPC: C08G18/65
Filed: 1997-10-07
Abstract: Bir bükülmez köpügün hazirlanacagi sekilde köpük olusturma kosullari altinda bir poliizosiyanat ve iki farkli poliolün reaksiyona sokulmasiyla, bu sekilde elde edilen bükülmez köpügün ezilmesiyle ve bu sekilde elde edilen bükülgen köpügün bir isi isleme tabi tutulmasiyla bir bükülgen poliüretan köpügün hazirlanmasi için islem. -100 C ve +25 C arasinda önemli bir cam geçis sicakligi arzetmeyen bükülgen köpükler elde edilmektedir.
Patent TR-199902082-T2 (TR)
Inventor: COX BRIAN
IPC: A61K31/495
Filed: 1998-02-26
Abstract: Bu bulus, merkezi sinir sistemi (CNS) hastaliklari ve düzensizliklerinde yararli olan yeni bir pirazin bilesikleri sinifina ve bunlarin farmasötik açidan kabul edilebilir türevleri, bunlari ihtiva eden farmasötik bilesimlere, bu tür düzensizliklerin iyilestirilmesinde kullanimlarina ve bunlarin hazirlanmasi için yöntemlere iliskindir.
Patent DE-60001156-T2 (DE)
Inventor: JENSEN HELMUTH
IPC: F02F3/22
Filed: 2000-03-17
Granted: 2003-10-02
Abstract: The piston comprises a piston top (3) which, at a distance from the longitudinal centre axis of the piston, has an abutment surface (7) extending in the circumferential direction of the piston and being clamped against an abutment surface (9) of a piston rod (2). The abutment surface (7) of the piston top (3) comprises a first surface (11) which, in a radially cross-sectional view, extends in a straight line and forms an angle of between 2 DEG  and 88 DEG  with a normal plane to the longitudinal centre axis of the piston, and a secondary surface (12) which forms an angle of less than 178 DEG  or more than 182 DEG  with the first surface (11).
Patent DE-60010331-T2 (DE)
Inventor: PAOLONE ROLANDO
IPC: B65G33/02
Filed: 2000-11-06
Granted: 2005-05-04
Abstract: In a machine for counting bars, for example metal bars, that are to be sent on to a packaging station which packages a pre-set number of them in bundles, the problem of precise counting of the bars is solved by using, for the conveyance of the bars to the counting station, a screw conveyor, in which each groove of the screw has a wall having a pitch increasing more rapidly as compared to the normal pitch of the screw, thus making it possible, in the case where more than one bar is present in the same groove, to render the lying plane of the bars not parallel to the specific axis of the counting means. This is obtained by providing one of the faces of the grooves either with a special step having a continuously increasing width, or with a continuously increasing inclination.
Patent DE-60015726-T2 (DE)
Inventor: TOH HOCK
IPC: A61B5/145
Filed: 2000-02-04
Granted: 2005-12-22
Abstract: Methods for predicting the presence of haemostatic dysfunction in a patient from a time-dependent measurement profile include performing a time-dependent measurement on an unknown sample and measuring a respective property over time so as to derive a time-dependent measurement profile. The slope of the time-dependent measurement profile is computed prior to clot formation. A biphasic waveform is detected in the time-dependent measurement profile based on the computed slope. The presence of haemostatic dysfunction in the patient is predicted based on the detected biphasic waveform.
Patent DE-60022107-T2 (DE)
Inventor: LOONTJES JACOBUS ANTONIUS
IPC: C08G18/66
Filed: 2000-02-21
Granted: 2006-06-22
Abstract: The invention relates to a compound comprising a reaction product of (A) an isocyanate functional compound of which at least 40 wt.%, relative to the total amount of (A), has a molecular weight of at least about 500, and (B) a nitrogen-containing compound capable of reacting with said isocyanate functional compound (A). The reaction product has a molecular weight of less than about 20,000 and comprises an effective amount of groups that are able to form reversible intermolecular physical interactions such that a resulting compound shows polymeric mechanical properties at a temperature below a transition temperature. The nitrogen-containing compound is, for instance, melamine, urea, acetoguanamine, benzoguanamine, cyanamide, dicyanamide, thiourea, isocytosine, pyrimidone or aminopyridine. The supramolecular compound comprising a suitable amount of the reaction products exhibits a relatively high elongation at break.
Patent DE-60022188-T2 (DE)
Inventor: BENEDINI FRANCESCA
IPC: A61K31/21
Filed: 2000-06-21
Granted: 2006-06-08
Abstract: Compounds of formula A-X1-ONO2 (I) in a partially or completely amorphous form and pharmaceutical compositions thereof.
Patent DE-60025200-T2 (DE)
Inventor: YONGE W
IPC: H04L7/00
Filed: 2000-04-25
Granted: 2006-09-07
Abstract: A mechanism for determining phases of a symbol for phase correlation is provided. The mechanism performs a symmetric apodizing window function on a symbol sample of a symbol having a symbol period of T and a time-offset symbol symbol sample offset from the symbol sample by T/2 to produce first windowed values for the symbol sample and second windowed values for the time-offset symbol sample. The mechanism applies a time shift to re-align the time-offset symbol sample with the symbol sample and sums the second windowed values and the corresponding first windowed values. The summed values are then converted to phases. The symmetric apodizing window function is an apodizing window function having the property Wj+W(FFTSize,/2+j)=constant, where FFTSize is the size of the FFT sample. The symmetric apodizing window function, such as a Hanning window, may be performed in the time or frequency domain.
Patent DE-60034042-T2 (DE)
Inventor: LEISTEN OLIVER PAUL
IPC: H01Q5/10
Filed: 2000-05-24
Granted: 2007-12-06
Abstract: A dielectrically-loaded antenna for operation at frequencies in excess of 200 MHz includes an antenna element structure disposed on a high dielectric constant core, which element structure comprises a pair of laterally opposed groups, of helical antenna elements. Each group comprises first and second mutually adjacent elements, of different thicknesses providing looped conductive paths on the antenna, formed by the first elements of each group and the second elements of each group respectively, which resonate at differing respective resonant frequencies to yield a relatively wide operating bandwidth. The helical elements of each group define, between them, part of an elongate channel which has an overall electrical length in the region of nlambd/2 within the operating frequency band to provide isolation between the looped conductive paths. The major part of each such channel is located between the elements so as to minimise intrusion with other parts of the antenna.
Patent DE-60037126-T2 (DE)
Inventor: WOJNOWSKI LESZEK
IPC: C12Q1/6883
Filed: 2000-09-08
Granted: 2008-09-18
Abstract: Described are general means and methods of diagnosing and treating the phenotypic spectrum as well as the overlapping clinical characteristics with several forms of inherited abnormal expression and/or function of the CYP3A4, CYP3A7 and hPXR genes. In particular, polynucleotides of molecular variant CYP3A4, CYP3A7 and hPXR genes which, for example, are associated with insufficient metabolization and/or sensitivety of drugs, and vectors comprising such polynucleotides are provided. Furthermore, host cells comprising such polynucleotides or vectors and their use for the production of variant CYP3A4, CYP3A7 and hPXR proteins are described. In addition, variant CYP3A4, CYP3A7 and hPXR proteins and antibodies specifically recognizing such proteins as well as transgenic non-human animals comprising the above-described polynucleotide or vectors are provided. Described are also methods for identifying and obtaining inhibitors for therapy of disorders related to the malfunction of the CYP3A4, CYP3A7 and hPXR genes as well as methods of diagnosing the status of such disorders. Pharmaceutical and diagnostic compositions comprising the above-described polynucleotides, vectors, proteins, antibodies and inhibitors by the above-described method are provided. Said compositions are particularly useful for diagnosing and treating various diseases with drugs that are substrates, inhibitors or modulators of the CYP3A4, CYP3A7 or hPXR gene product.